Outcome of the Second Quarter and Half Year Ended Financial Results ended 31th September, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.1 pts less than Nifty Microcap 250 and 5.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sanjivani Paranteral Ltd reported weak Q2 FY26 results, with standalone revenue from operations falling about 14.5% year-on-year to ₹1,549.73 lakhs and net profit dropping to ₹163.85 lakhs from ₹229.59 lakhs a year ago. For the first half of FY26, revenue declined to ₹3,338.95 lakhs (vs ₹3,456.81 lakhs) and net profit fell roughly 16% to ₹336.91 lakhs, with EPS at ₹2.74 versus ₹3.43. The company attributed the slowdown to external headwinds: lost export orders worth nearly ₹10 million in Nepal due to local unrest, tighter FDA scrutiny in Latin America, product approval delays in MENA, and the Iran-Israel conflict disrupting container movement, which together led to an unfavourable product mix and compressed EBITDA margins. Standalone operating cash flow remained negative at -₹246.05 lakhs for H1, though better than the -₹508.83 lakhs in the same period last year. The auditor (R.B. Gohil & Co.) issued an unqualified limited review report on both standalone and consolidated results.
Short-term results are clearly weak, with revenue, profit and margins all contracting due to temporary external factors. Shareholders may see near-term pressure on the stock given the YoY decline in earnings, but management is framing these issues as transient and is guiding that the demand pipeline and business fundamentals remain intact.